Judith I Sanchez, MD
Obstetrics/Gynecology · Gilroy
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 5 carriers
- Offices
- 3
Offices
3 locations · County of Santa Clara · 1,000 clinicians in this group
Looking this up.
Hospitals listed: Santa Clara Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
25 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sanchez’s office at (408) 885-5000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A79564 · Current
Licensed to practise in California · since 2002 · expires 2028-03-31 · University of California, Los Angeles School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas M7592Physician License · since 2007 · expires 2010-11-30Canc Non-RenewalNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Santa Clara Valley Medical CenterSan Jose, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Santa Clara Valley Health and Hospital System, which runs 3 hospitalsPatients rate it 3 of 5 · 70% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — SSI - Colon Surgery: 2.572, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.563, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.256, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.369, Oct 2024 – Sep 2025
See every measure and the patient survey for Santa Clara Valley Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 2.572 | Worse | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.563 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.256 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.369 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.25 (0.3 to 2.2) · 1,535 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.07 (0.76 to 1.38) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 214.59 (167.38 to 261.8) · 108 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 41 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6 · 141 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.2 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.3 · 501 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.9 · 653 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 348 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 4,502 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.24 (0.04 to 0.43) · 9,014 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.34 (0.15 to 0.52) · 9,216 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.54 (2.51 to 6.58) · 1,421 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.2) · 288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,446 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.61 (4.09 to 19.14) · 294 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.29 (3.39 to 11.2) · 299 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.9 (0.45 to 3.36) · 333 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.23 (0 to 0.78) · 7,538 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.4 · 94 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.735 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 2.573 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.6 · 185 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 951 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 56.3 · 128 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 6.4 · 644 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.3 · 699 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 921 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.9 to 8.1) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (9.4 to 16.5) · 226 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 94 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.4 · 54 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.3 · 242 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.4) · 702 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 195 cases | No different | Jan 2024 – Dec 2024 |
What patients said (4,032 patients answered, 29% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 2 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 82% |
| Yes, staff "did" give patients information about help after discharge | 82% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 67% |
| Staff "always" explained new medications | 71% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 69% |
| Nurses "always" treated them with courtesy and respect | 80% |
| "Always" quiet at night | 43% |
| "YES", patients would definitely recommend the hospital | 70% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 83% |
Medicaid work
$588,077 in 2024
Medicaid paid $588,077 for 7,292 billed services this clinician did in 2024, up to 112 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Clinic visit/encounter, all-inclusive | 1,121 | $573,587 |
| Short return visit (20+ min) | 1,368 | $4,336 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 76 | $3,438 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 77 | $1,848 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 167 | $1,608 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 166 | $1,598 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 77 | $920 |
| Prenatal care, at-risk enhanced service; education | 38 | $197 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 114 | $190 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 111 | $124 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 33 | $122 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 33 | $61 |
| 2024 | 7,292 | 24 | 112 | $588,077 |
| 2023 | 4,761 | 27 | 116 | $720,427 |
| 2022 | 4,233 | 34 | 121 | $647,303 |
| 2021 | 5,587 | 26 | 156 | $965,493 |
| 2020 | 4,179 | 16 | 138 | $778,587 |
| 2019 | 3,162 | 14 | 131 | $670,029 |
| 2018 | 4,740 | 27 | 170 | $971,164 |
See the largest Medicaid services in earlier years
2023
| Clinic visit/encounter, all-inclusive | 1,485 | $707,686 |
| Short return visit (20+ min) | 1,682 | $7,361 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 43 | $1,294 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 131 | $811 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 131 | $809 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 43 | $566 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 36 | $409 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 43 | $346 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 46 | $311 |
| Prenatal care, at-risk enhanced service; education | 29 | $254 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 110 | $173 |
| TREPONEMA PALLIDUM | 42 | $103 |
2022
| Clinic visit/encounter, all-inclusive | 1,276 | $630,519 |
| Short return visit (20+ min) | 835 | $4,711 |
| Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis | 72 | $2,854 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 205 | $1,786 |
| Short return visit | 439 | $1,590 |
| Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique | 72 | $1,271 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 152 | $1,247 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 151 | $1,244 |
| Infectious agent detection by nucleic acid (DNA or RNA); Trichomonas vaginalis, amplified probe technique | 71 | $764 |
| Prenatal care, at-risk enhanced service; education | 43 | $646 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 129 | $246 |
| TREPONEMA PALLIDUM | 51 | $165 |
2021
| Clinic visit/encounter, all-inclusive | 1,960 | $956,535 |
| Short return visit | 2,005 | $4,875 |
| Short return visit (20+ min) | 347 | $805 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 104 | $731 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 104 | $731 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 50 | $463 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 59 | $312 |
| TREPONEMA PALLIDUM | 72 | $272 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 146 | $268 |
| Prenatal care, at-risk enhanced service; education | 17 | $207 |
| Hemoglobin A1C level | 31 | $76 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 93 | $63 |
2020
| Clinic visit/encounter, all-inclusive | 1,956 | $768,219 |
| Payment for communication technology-based services for 5 minutes or more of a virtual (non-face-to-face) communication between an rural health clinic (rhc) or federally qualified health center (fqhc) practitioner and rhc or fqhc patient, or 5 minutes or more of remote evaluation of recorded video and/or images by an rhc or fqhc practitioner, occurring in lieu of an office visit; rhc or fqhc only | 313 | $4,451 |
| Short return visit (20+ min) | 1,190 | $3,565 |
| Short return visit | 385 | $952 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 53 | $494 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 53 | $493 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 18 | $124 |
| Prenatal care, at-risk enhanced service; education | 17 | $100 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 56 | $86 |
| TREPONEMA PALLIDUM | 27 | $81 |
| Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid) | 19 | $19 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 12 | $5 |
2019
| Clinic visit/encounter, all-inclusive | 1,682 | $664,551 |
| Short return visit (20+ min) | 944 | $3,685 |
| Preventive medicine counseling and risk factor reduction intervention for individual, approximately 15 minutes | 96 | $593 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 92 | $499 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 92 | $497 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 97 | $77 |
| TREPONEMA PALLIDUM | 40 | $56 |
| Thyroid stimulating hormone (TSH) | 13 | $38 |
| Culture, bacterial; aerobic isolate, additional methods required for definitive identification, each isolate | 12 | $12 |
| URINE BACTERIA CULTURE | 14 | $11 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; automated, with microscopy | 41 | $10 |
| Hemoglobin A1C level | 14 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 2,416 | $958,568 |
| Short return visit (20+ min) | 898 | $5,552 |
| Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia trachomatis, amplified probe technique | 261 | $2,131 |
| Infectious agent detection by nucleic acid (DNA or RNA); Neisseria gonorrhoeae, amplified probe technique | 261 | $2,124 |
| New patient visit (30+ min) | 46 | $999 |
| Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (eg, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68), pooled result | 48 | $537 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) | 157 | $212 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 39 | $162 |
| Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with screening by automated system and manual rescreening or review, under physician supervision | 110 | $153 |
| Hemoglobin A1C level | 63 | $111 |
| URINE PREGNANCY TEST | 130 | $101 |
| Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon | 12 | $95 |
Drugs they prescribed that Part D paid
$8,668
Pharmacies billed $8,668 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 133) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
117 generic and 16 brand-name prescriptions · $8,668 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Premarin | 13 | $5,047 | $388 |
| Estradiol | 24 | $1,571 | $65 |
| Progesterone | 11 | $304 | $28 |
| Oxybutynin Chloride Er | 14 | $103 | $7 |
Year by year
| 2024 | 133 | 37 | 0% (0) | 12% | $8,668 |
| 2023 | 159 | 38 | 0% (0) | 10% | $14,403 |
| 2022 | 170 | 38 | 0% (0) | 31% | $14,832 |
| 2021 | 146 | 39 | 0% (0) | None | $12,968 |
| 2020 | 123 | 30 | 0% (0) | 28% | $9,053 |
| 2019 | 106 | 32 | 0% (0) | 25% | $10,708 |
| 2018 | 90 | 23 | 0% (0) | 34% | $9,312 |
| 2017 | 53 | 16 | 0% (0) | 25% | $7,268 |
| 2016 | 33 | 16 | 0% (0) | None | $2,368 |
| 2015 | 69 | 21 | 0% (0) | None | $2,709 |
| 2014 | 59 | 21 | None | 22% | $3,206 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Premarin | 13 | $5,515 | $424 |
| Estradiol | 32 | $2,908 | $91 |
| Estradiol (Twice Weekly) | 20 | $2,237 | $112 |
| Oxybutynin Chloride Er | 14 | $476 | $34 |
| Progesterone | 18 | $470 | $26 |
2022: 6 drugs
| Premarin | 16 | $6,524 | $408 |
| Estradiol | 31 | $3,617 | $117 |
| Estradiol (Twice Weekly) | 13 | $1,872 | $144 |
| Tolterodine | 13 | $468 | $36 |
| Progesterone | 12 | $413 | $34 |
| Hydrocortisone | 16 | $90 | $6 |
2021: 3 drugs
| Estradiol | 35 | $3,035 | $87 |
| Clindamycin Phosphate | 11 | $851 | $77 |
| Tolterodine | 12 | $502 | $42 |
2020: 3 drugs
| Estradiol | 25 | $1,698 | $68 |
| Clindamycin Phosphate | 11 | $838 | $76 |
| Tolterodine | 12 | $641 | $53 |
2019: 2 drugs
| Estradiol | 28 | $3,805 | $136 |
| Tolterodine | 12 | $641 | $53 |
2018: 3 drugs
| Premarin | 11 | $3,911 | $356 |
| Estradiol | 13 | $2,098 | $161 |
| Tolterodine | 11 | $701 | $64 |
Money from drug and device companies
$226 in 2024
| 2024 | 3 | 3 | None | $226 |
| 2023 | 1 | 1 | None | $18 |
| 2019 | 1 | 1 | None | $98 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mayne Pharma Commercial | Annovera | $125 | 1 payment
|
| Bayer Healthcare Pharmaceuticals | Mirena | $65 | 1 payment
|
| Pfizer | Abrysvo | $37 | 1 payment
|
See all 3 published payments
| Pfizer | Meals · 2024-10-28 | Abrysvo | $37 |
| Mayne Pharma Commercial | Meals · 2024-09-18 | Annovera | $125 |
| Bayer Healthcare Pharmaceuticals | Meals · 2024-04-05 | Mirena | $65 |
See earlier years (2023, 2019)
2023: $18
| Organon | Nexplanon | $18 | 1 payment
|
2019: $98
| CooperSurgical | Paragard | $98 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 80.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1619987724
- Licence
- CA A79564, TX M7592California A79564: Current · expires 2028-03-31Texas M7592: Canc Non-Renewal
- Trained
- University of California, Geffen School of Medicine, 2000
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X); Federal specialty code 207VG0400X (207VG0400X); Federal specialty code 207VX0000X (207VX0000X)
- Mailing address
- 4900 Sunset Boulevard, Los Angeles, CA, 90027
- NPI first listed
- 2006-08-09
- NPI last updated
- 2009-08-05
This is when the NPI record was last certified, not a medical board exam.